News Archive
17 February 2010
Fourth Quarter Report 2009
Clavis Pharma delivers strong performance in the last quarter of 2009. CP-4126 development accelerated through partnership. Financial position further strengthened.
Fourth Quarter Report 2009
Clavis Pharma delivers strong performance in the last quarter of 2009. CP-4126 development accelerated through partnership. Financial position further strengthened.
8 January 2010
Clavis Pharma appoints Olav Hellebø as Chief Executive Officer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announced today that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.
Clavis Pharma appoints Olav Hellebø as Chief Executive Officer
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announced today that it has appointed Olav Hellebø as its new Chief Executive Officer (CEO). Mr Hellebø, who joins Clavis Pharma from UCB Pharma, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mr Hellebø will take up his position on 1st February 2010.
8 January 2010
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year.
Clavis Pharma receives US Orphan Drug Designation for CP-4126 to treat pancreatic cancer
Clavis Pharma (OSE: CLAVIS); the Norwegian cancer drug development company, announced today that the US Food & Drug Administration (FDA) has granted orphan drug designation to CP-4126 for the treatment of pancreatic cancer. The designation follows the equivalent designation given by the European Commission in October last year.
21 December 2009
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway to Support the Phase III Programme of Elacytarabine in Acute Myeloid Leukaemia
Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received an unsecured loan of NOK 20 million (USD 3.2 million) from Innovation Norway to support the Phase III clinical programme with Elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
Clavis Pharma ASA receives NOK 20 million Loan from Innovation Norway to Support the Phase III Programme of Elacytarabine in Acute Myeloid Leukaemia
Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received an unsecured loan of NOK 20 million (USD 3.2 million) from Innovation Norway to support the Phase III clinical programme with Elacytarabine in patients with late-stage acute myeloid leukaemia (AML).
7 December 2009
Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA. Elacytarabine is a novel, patented, lipid-conjugated form of the anti-cancer drug cytarabine (Ara-C) that has the potential to improve treatment outcomes in patients with AML and other haematological malignancies (leukaemias). Elacytarabine has Orphan Drug Designation in the USA and Europe for the treatment of AML.
Positive Phase II clinical data for Clavis Pharma's Elacytarabine presented at ASH Annual Meeting
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its Phase II study with its lead cancer product candidate elacytarabine in patients with late-stage acute myeloid leukaemia (AML) was presented at the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA, USA. Elacytarabine is a novel, patented, lipid-conjugated form of the anti-cancer drug cytarabine (Ara-C) that has the potential to improve treatment outcomes in patients with AML and other haematological malignancies (leukaemias). Elacytarabine has Orphan Drug Designation in the USA and Europe for the treatment of AML.